Mechanistically, LEP treatment was found to block the activation of PPARγ/NF-κB and STAT3 pathways by upregulating PPARγ expression and retarding the phosphorylation of NF-κB p65, IκB, and STAT3 in DSS-induced colitis. Here, NFKB1 is linked to colitis.